Preeti Sudheendra
Overview
Explore the profile of Preeti Sudheendra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
27
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azam S, Asad S, Chitnis S, Collier K, Kensler K, Sudheendra P, et al.
J Nutr
. 2024 Sep;
154(11):3437-3445.
PMID: 39277115
Background: The empirical dietary inflammation pattern score (EDIP), which measures the ability of the diet to regulate chronic inflammation, is associated with both higher adiposity and breast cancer (BC) risk....
2.
Sukumar J, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, et al.
Cancer Med
. 2024 Jun;
13(12):e7317.
PMID: 38895891
Background: The optimal adjuvant endocrine therapy (ET) in hormone receptor positive (HR+) and human epidermal growth factor receptor 2 positive (HER2+) premenopausal breast cancer (BC) remains unclear. Moreover, the benefit...
3.
Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, et al.
Support Care Cancer
. 2023 Nov;
31(12):717.
PMID: 37991653
Purpose: Dermatologic adverse events commonly result in the interruption of oncologic treatment, and targeted therapies are the most frequently interrupted class of anticancer agents. Alopecia is a common cutaneous adverse...
4.
Johnson K, Grimm M, Sukumar J, Schnell P, Park K, Stover D, et al.
Breast
. 2023 Oct;
72:103591.
PMID: 37871527
Inflammatory breast cancer (IBC) poses an ongoing challenge as rates of disease recurrence and mortality remain high compared to stage-matched controls. However, frontline therapy has evolved through the years, including...
5.
Johnson K, Goldstein D, Tharakan J, Quiroga D, Kassem M, Grimm M, et al.
Oncol Ther
. 2023 Jun;
11(3):361-374.
PMID: 37354381
Introduction: The immunomodulatory impact of corticosteroids and concurrent chemotherapy is poorly understood within triple-negative breast cancer (TNBC). On a biochemical level, steroids have been linked to the signaling of chemotherapy-resistant...
6.
Schieber T, Steele S, Collins S, Berger M, Fleming M, McLaughlin E, et al.
Clin Breast Cancer
. 2023 Jun;
23(6):658-663.
PMID: 37296062
Background: Palbociclib is indicated for the treatment of hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC) in combination with an aromatase inhibitor...
7.
Grimm M, Radcliff L, Giles M, Nash R, Holley E, Panda S, et al.
J Clin Med
. 2022 Jul;
11(14).
PMID: 35887755
Survivors of advanced breast cancer (ABC), also known as metavivors, are often left with fewer treatment options in the landscape of a cure culture. Metavivors have unique psychosocial and physical...
8.
Johnson K, Quiroga D, Sudheendra P, Wesolowski R
Expert Rev Anticancer Ther
. 2022 Apr;
22(5):505-522.
PMID: 35389302
Introduction: Since the advent of anti-HER2 therapies, evidence surrounding adjuvant treatment of small (T1mic, T1a, and T1b), node-negative, HER2-positive breast cancer (HER2+ BC) has remained limited. Practices vary widely between...
9.
Gandhi S, Sudheendra P, Rafferty W, Loveland-Jones C
Clin Breast Cancer
. 2018 Aug;
18(5):e751-e754.
PMID: 30131245
No abstract available.
10.
Rocque G, Blayney D, Jahanzeb M, Knape A, Markham M, Pham T, et al.
J Oncol Pract
. 2017 Aug;
13(11):e935-e943.
PMID: 28783425
Introduction: In 2012, ASCO created the Top Five Choosing Wisely (CW) list of low-value tests and procedures for which there is little evidence of benefit. ASCO's Quality Oncology Practice Initiative,...